161 related articles for article (PubMed ID: 20361090)
41. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Westbrook RH; Lea NC; Mohamedali AM; Smith AE; Orr DW; Roberts LN; Heaton ND; Wendon JA; O'Grady JG; Heneghan MA; Mufti GJ
Liver Transpl; 2012 Jul; 18(7):819-27. PubMed ID: 22467227
[TBL] [Abstract][Full Text] [Related]
42. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
[TBL] [Abstract][Full Text] [Related]
43. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
44. JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms.
Elf SE
Haematologica; 2021 Jul; 106(7):1783-1784. PubMed ID: 33567815
[No Abstract] [Full Text] [Related]
45. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
46. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder.
Bellucci S; Cassinat B; Bonnin N; Marzac C; Crassard I
Thromb Haemost; 2008 Jun; 99(6):1119-20. PubMed ID: 18521518
[No Abstract] [Full Text] [Related]
47. Budd-Chiari syndrome has different presentations and disease severity during adolescence.
Shukla A; Bhatt P; Gupta DK; Modi T; Patel J; Gupte A; Meshram M; Bhatia S
Hepatol Int; 2018 Nov; 12(6):560-566. PubMed ID: 29971683
[TBL] [Abstract][Full Text] [Related]
48. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
49. Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.
Fouassier M; Girodon F; Cleyrat C; Robillard N; Garand R; Hermouet S
Thromb Haemost; 2009 Jul; 102(1):180-2. PubMed ID: 19572087
[No Abstract] [Full Text] [Related]
50. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
51. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).
Hermouet S; Dobo I; Lippert E; Boursier MC; Ergand L; Perrault-Hu F; Pineau D
Leukemia; 2007 May; 21(5):1128-30. PubMed ID: 17301814
[No Abstract] [Full Text] [Related]
52. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
53. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
54. Progress in elucidation of molecular pathophysiology and its application in therapeutic decision-making for myeloproliferative neoplasms.
Takenaka K
Int J Hematol; 2020 Feb; 111(2):180-181. PubMed ID: 31907735
[No Abstract] [Full Text] [Related]
55. BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.
Martin-Cabrera P; Haferlach C; Kern W; Schnittger S; Haferlach T
Br J Haematol; 2017 Jan; 176(1):135-139. PubMed ID: 26847954
[No Abstract] [Full Text] [Related]
56. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
57. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
58. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P
Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656
[TBL] [Abstract][Full Text] [Related]
59. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
Kanellopoulou T; Alexopoulou A; Koskinas J
Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
[No Abstract] [Full Text] [Related]
60. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders.
Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC
Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
